Novartis' newly acquired Arzerra (ofatumumab) is up against some hefty competition in chronic lymphocytic leukemia (CLL). But the Swiss drugmaker has a plan for helping it achieve its sales potential.
Thanks to the companies' recent multi-billion-dollar asset swap, Novartis already has the rights to former GlaxoSmithKline drug ofatumumab's cancer applications. But now, it's forking over up to $1 billion to gain full control of the med--currently marketed as Arzerra--and to test it as a therapy for multiple sclerosis.
Novartis is paying GlaxoSmithKline as much as $1 billion for the rights to a mid-stage multiple sclerosis treatment, betting it can develop an heir to the blockbuster Gilenya, soon to lose patent protection.
Over the past few years, Aveo Oncology has watched each of its most promising cancer treatments flame out, but pharma giant Novartis sees potential in one of the company's early-stage assets, and the Swiss drugmaker has come through with a deal worth up to $326 million to partner on the project.
Novartis is working hard to build up market share for new psoriasis med Cosentyx ahead of its forthcoming competition, and it's signed on '80s icon Cyndi Lauper to help.
How can girls with psoriasis have fun? '80s icon Cyndi Lauper says she knows--and she has teamed up with Novartis to talk about it.
Actelion's Tracleer was recommended by Japan's Pharmaceutical Affairs and Food Sanitation Council (PAFSC) for an additional indication aimed at reducing ulcers in patients with generalized scleroderma, a spokesman for the Ministry of Health Labor and Welfare said.
Irish CRO Icon has signed on to be the exclusive service provider for a new U.K. biotech startup, planning to help the nascent company advance a trio of Novartis-developed drugs.
Novartis has faced safety questions on its multiple sclerosis pill Gilenya before, prompted by reports of progressive multifocal leukoencephalopathy in its users. Now, the FDA is updating the drug's official label to highlight two more PML reports in patients not previously treated with immunosuppressant drugs.
Novartis is dealing with more regulatory pushback on its MS med Gilenya as the agency said it will update Gilenya's label to reflect cases of serious brain infections linked to the pill.